Robert M Plenge insider trades

Open-market stock purchases and sales by Robert M Plenge, Director at Biomarin Pharmaceutical Inc, from SEC Form 4 filings since Apr 10, 2019.

Recent trades

DateStockTradeValue
Sep 10, 2026BMRN Biomarin Pharmaceutical IncBought (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoSold (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoSold (not open market)$26.2K
Mar 10, 2026BMY Bristol Myers Squibb CoSold (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoSold (not open market)$55.7K
Mar 10, 2026BMY Bristol Myers Squibb CoSold (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoSold (not open market)$191K
Mar 10, 2026BMY Bristol Myers Squibb CoBought (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoBought (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoBought (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoBought (not open market)—
Mar 10, 2026BMY Bristol Myers Squibb CoBought (not open market)—

Companies traded

  • BMRN Biomarin Pharmaceutical Inc: other filings, last Sep 10, 2026
  • BMY Bristol Myers Squibb Co: 1 sale, last Mar 10, 2026
  • TBIO Translate Bio, Inc: 3 sales, last Sep 14, 2021

Get free alerts when Robert M Plenge files a new trade →